[Pulmonary hypertension, endothelial dysfunction, and their correction with lisinopril in patients with heart failure in combination of ischemic heart disease and chronic obstructive pulmonary disease].
The paper contains review of the role of endothelial dysfunction in heart failure in patients with combination of ischemic heart disease and chronic obstructive pulmonary disease and discussion of results of a study in which it was established that lisinopril (10 mg/day) caused attenuation of pulmonary hypertension, improvement of right ventricular systolic function and diastolic ventricular filling at the background of correction of vascular tone.
Pribylov
S A
SA
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004730:Endothelium, Vascular / Q000503:physiopathology*; D005260:Female; D006333:Heart Failure / Q000175:diagnosis / Q000453:epidemiology / Q000503:physiopathology; D006801:Humans; D006976:Hypertension, Pulmonary / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology; D017706:Lisinopril / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000175:diagnosis / Q000453:epidemiology / Q000503:physiopathology; D029424:Pulmonary Disease, Chronic Obstructive / Q000453:epidemiology*
D000806:Angiotensin-Converting Enzyme Inhibitors; D017706:Lisinopril